AXSOME THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
AXSOME THERAPEUTICS, INC. (AXSM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$2.79 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-15.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2019-03-15
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-12-31 was -$102.00K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-09-30 was -$15.00K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-06-30 was -$1.00K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-03-31 was -$2.67M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was -$2.79M, a 532.04% decline from fiscal 2017.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was $646.00K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2015 was -$166.26K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2014 was -$124.89K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | -$117.00K derived: sum of 2 quarters · filed 2019-03-15 | -$118.00K derived: sum of 3 quarters · filed 2019-03-15 | -$2.79M 10-K · filed 2019-03-15 |
| 2018-09-30 | -$15.00K 10-Q · filed 2018-11-09 | -$16.00K derived: sum of 2 quarters · filed 2018-11-09 | -$2.69M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$1.00K 10-Q · filed 2018-08-08 | -$2.67M 10-Q · filed 2018-08-08 | ||
| 2018-03-31 | -$2.67M derived: 10-K 12 month − 3 quarters · filed 2019-03-15 | |||
| 2017-12-31 | $646.00K 10-K · filed 2019-03-15 | |||
| 2015-12-31 | -$426.50K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$254.50K derived: sum of 2 quarters · filed 2018-03-07 | -$88.03K derived: sum of 3 quarters · filed 2018-03-07 | -$166.26K 10-K · filed 2018-03-07 |
| 2015-09-30 | $172.00K 10-Q · filed 2016-11-14 | $338.47K derived: sum of 2 quarters · filed 2016-11-14 | $260.24K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $166.47K 10-Q · filed 2016-08-09 | $88.24K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$78.23K 10-Q/A · filed 2016-08-09 | |||
| 2014-12-31 | -$124.89K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |